Status:
UNKNOWN
Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.
Lead Sponsor:
The Netherlands Cancer Institute
Collaborating Sponsors:
AstraZeneca
Conditions:
Non-small-cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Initially, patients with EGFR mutation positive NSCLC respond well to osimertinib, a third generation EGFR tyrosine kinase inhibitor (TKI), but eventually progress. Upon progression multiple resistanc...
Detailed Description
Initially, patients with EGFR mutation positive NSCLC respond well to osimertinib, a third generation EGFR tyrosine kinase inhibitor (TKI), but eventually progress. Upon progression, three main resist...
Eligibility Criteria
Inclusion
- Histologically confirmed metastatic NSCLC, characterized by a sensitizing EGFR mutation.
- 2\. Progressive disease, as assessed by the treating physician during osimertinib monotherapy.
- 3\. Eligible for subsequent treatment. 4. Willing to undergo a histological biopsy and withdrawal of a blood sample for ctDNA analysis.
- 5\. Technically possible to take a histological biopsy.
Exclusion
- \- 1. Osimertinib discontinuation before blood draw and / or histological tumor biopsy.
- 2\. Initiation of a new line of anticancer therapy before blood draw and / or histological tumor biopsy.
Key Trial Info
Start Date :
August 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 22 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04737382
Start Date
August 22 2019
End Date
August 22 2024
Last Update
October 10 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
The Netherlands Cancer Institute-Antoni van Leeuwenhoek
Amsterdam, North Holland, Netherlands, 1066 CX
2
Vrije Universiteit Medisch Centrum
Amsterdam, Netherlands
3
Universitair Medisch Centrum Groningen
Groningen, Netherlands
4
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands